SCHEMBL5865870

SCHEMBL5865870

Cn1c(=O)cc(C(F)(F)F)c2cc(S(=O)(=O)N3Cc4ccccc4C3)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
USP2 O75604 2/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
HSD17B10 Q99714 1/20 0.45
AR P10275 7/20 0.44
PGR P06401 4/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
AKR1C3 P42330 1/20 0.41
AKR1C1 Q04828 1/20 0.41
HSD11B1 P28845 1/20 0.41
PARG Q86W56 1/20 0.40
KDM4E B2RXH2 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865901 0.83 HSD17B10 (0.57) ALDH1A1USP2HPGDTSHRHSD17B10
SCHEMBL5865914 0.83 HSD17B10 (0.57) ALDH1A1USP2HPGDTSHRHSD17B10
SCHEMBL5865876 0.80 ALDH1A1 (0.64) ALDH1A1TSHRMEN1KMT2AAKR1C3
SCHEMBL5865911 0.80 ALDH1A1 (0.48) ALDH1A1USP2HPGDTSHRHSD17B10
SCHEMBL5865882 0.80 SMN1; SMN2 (0.61) ALDH1A1USP2HPGDTSHRHSD17B10
SCHEMBL5865892 0.80 POLB (0.48) ALDH1A1USP2HPGDTSHRHSD17B10
SCHEMBL6022453 0.77 AR (0.48) ALDH1A1USP2HPGDTSHRHSD17B10
SCHEMBL6023005 0.77 PIK3CG (0.57) ALDH1A1ARPGRPARGNR3C1
SCHEMBL5865904 0.77 PARG (0.47) ARPGRPARGNR3C1NR3C2
SCHEMBL5865893 0.77 PARG (0.50) ARPGRPARGNR3C1NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064207-B2 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin WARNER LAMBERT COMPANY LLC (US) 2006-06-20 US claimed
US-20050085467-A1 Androgen receptor antagonists DU DANIEL Y (US) 2005-04-21 US claimed
US-7064207-B2 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin WARNER LAMBERT COMPANY LLC (US) 2006-06-20 US disclosed
EP-1587804-A1 ANDROGEN RECEPTOR ANTAGONISTS Warner-Lambert Company LLC (US) 2005-10-26 EP disclosed
US-20050085467-A1 Androgen receptor antagonists DU DANIEL Y (US) 2005-04-21 US disclosed
WO-2004065379-A1 ANDROGEN RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085467-A1 Androgen receptor antagonists AR, NR5A1, ESRRB ALDH1A1 1431/4885USP2 1378/4885HPGD 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.